Cover Image
市場調查報告書

癌症食慾不振惡病質症候群:開發中產品分析

Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 484626
出版日期 內容資訊 英文 93 Pages
訂單完成後即時交付
價格
Back to Top
癌症食慾不振惡病質症候群:開發中產品分析 Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 93 Pages
簡介

所謂食慾不振,定義為食慾衰退。進行性的衰弱在各種癌症都共通,是導致癌症患者早期死亡的最大要素之一。癌症食慾不振,或是惡病質,與衰弱,疲勞及生活品質降低常有關聯。由於患者無法參與聚餐,食慾不振的症狀不僅是患者本人,往往也影響其家族。

本報告提供全球各國的癌症食慾不振惡病質症候群治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

簡介

  • 調查範圍

癌症食慾不振惡病質症候群;概要

癌症食慾不振惡病質症候群 - 治療藥的開發

  • 開發中產品 概要
  • 開發中產品:各企業
  • 開發中產品:各大學/研究機關
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Acacia Pharma Ltd
  • Aeterna Zentaris Inc
  • Aphios Corp
  • Incyte Corp
  • Lakewood-Amedex Inc
  • Novartis AG
  • Obexia AG
  • PsiOxus Therapeutics Ltd
  • RaQualia Pharma Inc
  • Viking Therapeutics Inc

藥物簡介

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9697IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2017, provides an overview of the Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline landscape.

Anorexia is defined as the loss of the desire to eat. Progressive wasting is common in many types of cancer and is one of the most important factors leading to early death in cancer patients. Advanced cancer undergo a wasting syndrome associated with cancer anorexia/cachexia and asthenia. Cancer anorexia or cachexia often is associated with weakness, fatigue, and a poor quality of life. This symptom of anorexia not only affects the patient but also frequently has an impact on family members, as the patient is no longer able to participate fully in eating as a social activity.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cancer Anorexia-Cachexia Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 1, 1, 9 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.

Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Anorexia-Cachexia Syndrome (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cancer Anorexia-Cachexia Syndrome - Overview
    • Cancer Anorexia-Cachexia Syndrome - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cancer Anorexia-Cachexia Syndrome - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cancer Anorexia-Cachexia Syndrome - Companies Involved in Therapeutics Development
    • Abreos Biosciences Inc
    • Acacia Pharma Ltd
    • Aeterna Zentaris Inc
    • Incyte Corp
    • Lakewood-Amedex Inc
    • Novartis AG
    • Paradigm Biopharmaceuticals Ltd
    • RaQualia Pharma Inc
    • Viking Therapeutics Inc
    • Zeria Pharmaceutical Co Ltd
  • Cancer Anorexia-Cachexia Syndrome - Drug Profiles
    • (formoterol fumarate + megestrol acetate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • anamorelin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AV-380 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVGN-7 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-1889 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DLN-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ENERGIF-706 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EXT-400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Foxo1-nRNA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fusion Protein to Inhibit Activin A for Osteoporosis and Cancer Cachexia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HM-03 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IP-1510 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • macimorelin acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NEO-1940 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Peptide to Inhibit CIDEA for Cancer Cachexia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RQ-00433412 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ruxolitinib phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Cancer Cachexia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TCMCB-07 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VK-5211 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Z-505 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cancer Anorexia-Cachexia Syndrome - Dormant Projects
  • Cancer Anorexia-Cachexia Syndrome - Discontinued Products
  • Cancer Anorexia-Cachexia Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • May 18, 2017: Helsinn Announces Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride)
      • Feb 13, 2017: Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen
      • Jun 01, 2016: Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis From two Phase III Studies for Anamorelin in Cachectic Patients With Non-small Cell Lung Cancer
      • Feb 23, 2016: Helsinn Announces Publication of Anamorelin ROMANA 1 and ROMANA 2 Phase III Studies in The Lancet Oncology
      • Nov 30, 2015: Helsinn Announces European Medicines Agency Acceptance of Marketing Authorization Application for Anamorelin HCL
      • Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology
      • Sep 26, 2014: AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference
      • Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130
      • Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130
      • Dec 07, 2011: Helsinn Initiates Extension Study In Late-Stage Anamorelin Clinical Program For Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia
      • Dec 06, 2011: Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study
      • Nov 28, 2011: FDA Grants IND To Investigator At Baylor College Of Medicine For Phase IIa Trial With AEZS-130 In Cancer Cachexia
      • Aug 24, 2011: Helsinn Therapeutics Initiates Phase III Clinical Program To Evaluate Anamorelin In Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia
      • Apr 26, 2007: Sapphire Therapeutics, Inc. to Present Results From Anamorelin Phase II Cachexia/Anorexia Studies at American Society of Clinical Oncology and Endocrine Society Annual Meetings in June
      • Dec 15, 2005: Sapphire Therapeutics, Inc.'s Oral Ghrelin Mimetic Shows Potential for Treating Cancer Anorexia/Cachexia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Pipeline by Abreos Biosciences Inc, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Pipeline by Acacia Pharma Ltd, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Pipeline by Aeterna Zentaris Inc, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Pipeline by Incyte Corp, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Pipeline by Lakewood-Amedex Inc, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Pipeline by Novartis AG, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Pipeline by RaQualia Pharma Inc, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Pipeline by Viking Therapeutics Inc, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Pipeline by Zeria Pharmaceutical Co Ltd, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Dormant Projects, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top